COCP

Insider Trades

Name	Value	Action	Price	Current Price
Frost Phillip MD Et AlDirector, 10 Percent Owner: $20k20k shares BuyFeb 24, 2026 $0.9976 --
Frost Phillip MD Et AlDirector, 10 Percent Owner: $47k50k shares BuyFeb 6, 2026 $0.9456 --
Frost Phillip MD Et AlDirector, 10 Percent Owner: $47k50k shares BuyDec 31, 2025 $0.9455 --
Frost Phillip MD Et AlDirector, 10 Percent Owner: $19k20k shares BuyDec 30, 2025 $0.9655 --
Frost Phillip MD Et AlDirector, 10 Percent Owner: $39k40k shares BuyDec 26, 2025 $0.9736 --
Frost Phillip MD Et AlDirector, 10 Percent Owner: $24k25k shares BuyDec 24, 2025 $0.9703 --

News

globenewswire.comCocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officerglobenewswire.comJun 3

globenewswire.comCocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenzaglobenewswire.comMay 26

globenewswire.comCocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Resultsglobenewswire.comMay 15

globenewswire.comCocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infectionglobenewswire.comApr 30

Trade COCP

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-31244, a non-nucleoside polymerase inhibitor for HCV, which has successfully completed Phase IIa clinical trials. Additionally, CC-42344, a PB2 inhibitor designed to combat influenza, is currently undergoing preclinical development. Cocrystal Pharma is also actively pursuing the development of non-nucleoside polymerase inhibitors to address norovirus infections. The company maintains strategic alliances, including a research and licensing collaboration with Merck Sharp & Dohme Corp. for the discovery and development of proprietary influenza A/B antiviral agents. It also holds a licensing agreement with the Kansas State University Research Foundation, aimed at advancing antiviral compounds for norovirus and coronavirus infections. Furthermore, Cocrystal Pharma engages in drug discovery collaborations with both HitGen and InterX Inc. The company's operations are headquartered in Bothell, Washington.

CEO: Sam Lee
IPO Date: Feb 22, 2012

Market Data

Open: $0.955
High: $0.9963
Low: $0.9501
Volume: 73.3K
Avg Volume: 2.4M
52W High: $2.67
52W Low: $0.86

Valuation

Market Cap: $10M
Enterprise Value: $6.9M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-8.2M
Revenue: $0
Net Income: $-8.8M
Cash: $7.0M
Debt: $1.5M

Events

EarningsAug 13

EPS est. -0.17